WO2024025936A3 - Développement de vaccins anti-salmonella à base de glucides - Google Patents

Développement de vaccins anti-salmonella à base de glucides Download PDF

Info

Publication number
WO2024025936A3
WO2024025936A3 PCT/US2023/028672 US2023028672W WO2024025936A3 WO 2024025936 A3 WO2024025936 A3 WO 2024025936A3 US 2023028672 W US2023028672 W US 2023028672W WO 2024025936 A3 WO2024025936 A3 WO 2024025936A3
Authority
WO
WIPO (PCT)
Prior art keywords
salmonella
capsid
carbohydrate
development
based anti
Prior art date
Application number
PCT/US2023/028672
Other languages
English (en)
Other versions
WO2024025936A2 (fr
Inventor
Xuefei Huang
Xingling PAN
Chang-xin HUO
Scott Michael BALIBAN
Sharon Mei TENNANT
Original Assignee
Board Of Trustees Of Michigan State University
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Michigan State University, University Of Maryland, Baltimore filed Critical Board Of Trustees Of Michigan State University
Publication of WO2024025936A2 publication Critical patent/WO2024025936A2/fr
Publication of WO2024025936A3 publication Critical patent/WO2024025936A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition de vaccin comprenant un antigène de Salmonella conjugué à une capside, la capside comprenant une séquence native ou de type sauvage. L'invention concerne également une composition de vaccin comprenant un antigène de Salmonella conjugué à une capside, ladite capside comprenant au moins une mutation, telle qu'une mutation non naturelle. De telles compositions sont utiles dans le traitement et la prévention pour prévenir ou traiter une infection à Salmonella (salmonellose), la gastroentérite, la fièvre typhoïde et/ou la fièvre paratyphoïde; et peuvent être efficaces contre de multiples souches de Salmonella.
PCT/US2023/028672 2022-07-26 2023-07-26 Développement de vaccins anti-salmonella à base de glucides WO2024025936A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263392274P 2022-07-26 2022-07-26
US63/392,274 2022-07-26

Publications (2)

Publication Number Publication Date
WO2024025936A2 WO2024025936A2 (fr) 2024-02-01
WO2024025936A3 true WO2024025936A3 (fr) 2024-03-28

Family

ID=89707149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/028672 WO2024025936A2 (fr) 2022-07-26 2023-07-26 Développement de vaccins anti-salmonella à base de glucides

Country Status (1)

Country Link
WO (1) WO2024025936A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052544A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same
US20130129776A1 (en) * 2011-11-07 2013-05-23 University Of Maryland, Baltimore Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease
WO2019045791A1 (fr) * 2017-08-28 2019-03-07 Board Of Trustees Of Michigan State University Compositions et méthodes de traitement du cancer et des infections à l'aide d'un bactériophage et de ses mutants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052544A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same
US20130129776A1 (en) * 2011-11-07 2013-05-23 University Of Maryland, Baltimore Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease
WO2019045791A1 (fr) * 2017-08-28 2019-03-07 Board Of Trustees Of Michigan State University Compositions et méthodes de traitement du cancer et des infections à l'aide d'un bactériophage et de ses mutants
US20200261559A1 (en) * 2017-08-28 2020-08-20 Board Of Trustees Of Michigan State University Compositions and methods of treating cancer and infections using bacteriophage and its mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEBASHIS DHARA: "Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti‐Paratyphoid Fever Vaccines", CHEMISTRY - A EUROPEAN JOURNAL, JOHN WILEY & SONS, INC, DE, vol. 26, no. 68, 4 December 2020 (2020-12-04), DE, pages 15953 - 15968, XP093156450, ISSN: 0947-6539, DOI: 10.1002/chem.202002401 *

Also Published As

Publication number Publication date
WO2024025936A2 (fr) 2024-02-01

Similar Documents

Publication Publication Date Title
RU2009138344A (ru) Способ консервации вирусных частиц
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
UY26801A1 (es) Composición de vacuna
Carter et al. Growth of typhoid and paratyphoid bacilli in intravenously infected mice
WO2022140364A3 (fr) Vaccins contre le virus de la peste porcine africaine (ppa)
CL2008003202A1 (es) Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
CO5300414A1 (es) Composiciones de vacunas con antigenos de streptococus de virus vsr y adyuvante estimulador de respuesta th1
AR001618A1 (es) Adyuvante de saponina del arbol quillajay y formulacion de vacuna que contiene el mismo
MX2023013434A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
AR117921A1 (es) Cepa modificada de salmonella enterica typhi
ES2052042T3 (es) Procedimiento de estabilizacion de las vacunas y asociaciones de vacunas de virus atenuados conservadas en forma liofilizada, y composiciones obtenidas.
WO2024025936A3 (fr) Développement de vaccins anti-salmonella à base de glucides
CY1107538T1 (el) Εμβολιο μυκοπλασματος αδρανοποιημενο με σαπωνινη
Choi et al. Pathogenicity and antigenicity of a new variant of Korean nephropathogenic infectious bronchitis virus
CO5721019A2 (es) Aislados y vacunas antigenicos de virus de bursitis infecciosa
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada
Deng et al. Quantitative studies of the regular distribution pattern for Salmonella enteritidis in the internal organs of mice after oral challenge by a specific real-time polymerase chain reaction
ATE155690T1 (de) Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene
BR0111223A (pt) Composição de vacina tetravalente contra a dengue
WO2021044436A3 (fr) Compositions immunogènes contre des maladies entériques et leurs procédés de préparation
Rishi et al. Modulatory effects of Salmonella LAP-LPS on murine macrophages
RU2494758C2 (ru) Нейссериальные вакцинные композиции, содержащие комбинацию антигенов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847294

Country of ref document: EP

Kind code of ref document: A2